GLP-1 Medicines and Gallbladder Problems: What Research Shows

Gallbladder concerns are one reason a new or severe abdominal symptom should not be brushed off during GLP-1 treatment. A 2022 systematic review and meta-analysis of 76 randomized clinical trials involving more than 103,000 participants found that people assigned to GLP-1 receptor agonists had a higher risk of gallbladder or biliary diseases (relative risk 1.37, roughly a 37% relative increase). The association was stronger in weight-loss trials, at higher doses and with longer treatment. A 2025 meta-analysis of 55 placebo-controlled trials (about 106,000 participants) similarly found more gallstones, but in absolute terms that was about 2 extra cases per 1,000 people. Relative risk is not the same as your individual, absolute risk.

What the labels show

In the US prescribing information, gallstones (cholelithiasis) were reported in 1.6% of adults on Wegovy 2.4 mg versus 0.7% on placebo, and gallbladder inflammation (cholecystitis) in 0.6% versus 0.2%. In the Zepbound weight trials, cholelithiasis occurred in 1.1% versus 1.0% and cholecystitis in 0.7% versus 0.2%. Both labels include a warning about acute gallbladder disease.

Is the medicine or the weight loss responsible?

The relationship may involve more than one mechanism. Rapid weight loss itself is a known risk factor for gallstones (MedlinePlus lists rapid weight loss from very low-calorie diets or after weight-loss surgery), and the Zepbound label notes that acute gallbladder events were associated with weight reduction. The medicines may also affect gallbladder function, which is still being studied. Symptoms alone cannot tell you the cause in an individual case. A prior history of gallstones or gallbladder disease is important context for a clinician reviewing treatment.

What symptoms are worth knowing?

Gallbladder problems can cause pain in the upper right or upper middle abdomen, often lasting 30 minutes or more and sometimes after meals, and may come with nausea or vomiting. Fever, yellowing of the skin or eyes, dark urine, pale or clay-colored stools, or pain lasting several hours warrant prompt evaluation. These symptoms overlap with other conditions, including pancreatitis, so they are not a home diagnostic checklist. If pain is severe, see severe stomach pain on GLP-1.

Should this stop someone from considering treatment?

A group-level risk signal does not decide treatment for every person. Benefits, alternatives, medical history, dose, expected treatment duration and your preferences all matter. A clinician can explain the product-specific label and what symptoms should prompt contact. Do not stop, restart or adjust a medicine without professional guidance unless emergency services instruct otherwise.

Questions to ask

• Does my past history of gallstones change the discussion?
• Which abdominal symptoms should prompt same-day advice or emergency care?
• How should my treatment be reviewed if I experience rapid weight change?
• Are other medicines or conditions relevant to my risk?

The honest takeaway is neither "gallstones are inevitable" nor "there is nothing to worry about." The research supports awareness and timely assessment, not panic or self-diagnosis.